Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Effects of β-Adrenergic Antagonists on Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Chaudhary KR, Yan SX, Heilbroner SP, Sonett JR, Stoopler MB, Shu C, Halmos B, Wang TJC, Hei TK, Cheng SK.

J Clin Med. 2019 Apr 26;8(5). pii: E575. doi: 10.3390/jcm8050575.

2.

Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC "capitulate"?

Ko B, Halmos B.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S321-S325. doi: 10.21037/tlcr.2018.12.05. No abstract available.

3.

Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma.

Sukrithan V, Sandler J, Gucalp R, Gralla R, Halmos B.

Clin Lung Cancer. 2019 May;20(3):e242-e246. doi: 10.1016/j.cllc.2018.12.013. Epub 2018 Dec 24. No abstract available.

PMID:
30665873
4.

Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved Community.

Su CT, Chau V, Halmos B, Shah CD, Gucalp RA, Packer SH, Wilson K, Rapkin BD, Perez-Soler R, Cheng H.

Am J Clin Oncol. 2019 Mar;42(3):298-303. doi: 10.1097/COC.0000000000000516.

PMID:
30663997
5.

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).

Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E.

Lung Cancer. 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2.

6.

Expanding the gamut of circulating tumor DNA applications.

Kaumaya M, Halmos B.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4151-S4155. doi: 10.21037/jtd.2018.10.87. No abstract available.

7.

VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?

Alexander M, Halmos B.

Ann Transl Med. 2018 Dec;6(23):446. doi: 10.21037/atm.2018.11.20. No abstract available.

8.

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.

Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T.

Future Oncol. 2018 Nov;14(27):2861-2874. doi: 10.2217/fon-2018-0711. Epub 2018 Oct 19.

9.

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators.

N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.

10.

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature.

Deng L, Sharma J, Ravera E, Halmos B, Cheng H.

Lung Cancer (Auckl). 2018 Sep 6;9:73-77. doi: 10.2147/LCTT.S173948. eCollection 2018.

11.

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.

Deng L, Kiedrowski LA, Ravera E, Cheng H, Halmos B.

J Thorac Oncol. 2018 Sep;13(9):e169-e172. doi: 10.1016/j.jtho.2018.04.007. No abstract available.

PMID:
30166014
12.

Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community.

Su CT, Bhargava A, Shah CD, Halmos B, Gucalp RA, Packer SH, Ohri N, Haramati LB, Perez-Soler R, Cheng H.

Clin Lung Cancer. 2018 Sep;19(5):e767-e773. doi: 10.1016/j.cllc.2018.05.019. Epub 2018 Jun 5.

PMID:
29937386
13.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, Schneider B, Sukari A, Ventimiglia J, Chen W, Galasso C, Wozniak A, Boerner J, Kalemkerian GP.

J Thorac Oncol. 2018 Sep;13(9):1393-1399. doi: 10.1016/j.jtho.2018.05.002. Epub 2018 Jul 17.

PMID:
29775808
14.

Molecular Testing in Lung Cancer: Where to Draw the Line?

Halmos B.

Arch Pathol Lab Med. 2018 Jul;142(7):787-789. doi: 10.5858/arpa.2018-0060-ED. Epub 2018 Apr 6. No abstract available.

PMID:
29624077
15.

Biomarker use in lung cancer management: expanding horizons.

Sandler JE, Kaumaya M, Halmos B.

Biomark Med. 2018 Apr;12(4):315-320. doi: 10.2217/bmm-2018-0028. Epub 2018 Mar 23. No abstract available.

PMID:
29569465
16.

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Cheng H, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, Halmos B, Perez-Soler R, Zang X.

Clin Cancer Res. 2018 Apr 15;24(8):1954-1964. doi: 10.1158/1078-0432.CCR-17-2924. Epub 2018 Jan 26.

17.

Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Ohri N, Bodner WR, Kabarriti R, Shankar V, Cheng H, Abraham T, Halmos B, Gucalp R, Perez-Soler R, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):709-715. doi: 10.1016/j.ijrobp.2017.10.032. Epub 2017 Oct 28.

PMID:
29249527
18.

EGFR T790M: revealing the secrets of a gatekeeper.

Ko B, Paucar D, Halmos B.

Lung Cancer (Auckl). 2017 Oct 9;8:147-159. doi: 10.2147/LCTT.S117944. eCollection 2017. Review.

19.

Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.

Attarian S, Rahman N, Halmos B.

Ann Transl Med. 2017 Sep;5(18):377. doi: 10.21037/atm.2017.07.18. Review.

20.

Emerging uses of biomarkers in lung cancer management.

Halmos B, Levy B.

Ann Transl Med. 2017 Sep;5(18):370. doi: 10.21037/atm.2017.08.19. No abstract available.

21.

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Smith MA, Licata T, Lakhani A, Garcia MV, Schildhaus HU, Vuaroqueaux V, Halmos B, Borczuk AC, Chen YA, Creelan BC, Boyle TA, Haura EB.

Clin Cancer Res. 2017 Nov 15;23(22):7084-7096. doi: 10.1158/1078-0432.CCR-16-3006. Epub 2017 Aug 29.

22.

Efficacy and Safety Results of the Afatinib Expanded Access Program.

Kim ES, Halmos B, Kohut IF, Patel T, Rostorfer RD, Spira AI, Cseh A, McKay J, Wallenstein G, Mileham KF.

Oncol Ther. 2017;5(1):103-110. doi: 10.1007/s40487-017-0043-5. Epub 2017 Apr 10.

23.

DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.

Castellucci E, He T, Goldstein DY, Halmos B, Chuy J.

Oncologist. 2017 May;22(5):497-502. doi: 10.1634/theoncologist.2017-0034. Epub 2017 May 2.

24.

Continuous Activity Monitoring During Concurrent Chemoradiotherapy.

Ohri N, Kabarriti R, Bodner WR, Mehta KJ, Shankar V, Halmos B, Haigentz M Jr, Rapkin B, Guha C, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1061-1065. doi: 10.1016/j.ijrobp.2016.12.030. Epub 2016 Dec 25.

25.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.

Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ.

J Thorac Oncol. 2017 Jun;12(6):932-942. doi: 10.1016/j.jtho.2017.03.005. Epub 2017 Mar 16.

26.

MET/HGF pathway activation as a paradigm of resistance to targeted therapies.

Ko B, He T, Gadgeel S, Halmos B.

Ann Transl Med. 2017 Jan;5(1):4. doi: 10.21037/atm.2016.12.09. Review.

27.

18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Ohri N, Bodner WR, Halmos B, Cheng H, Perez-Soler R, Keller SM, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):372-380. doi: 10.1016/j.ijrobp.2016.10.031. Epub 2016 Oct 26.

PMID:
28068244
28.

The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy.

Sharma J, Shum E, Chau V, Paucar D, Cheng H, Halmos B.

Respiration. 2017;93(1):1-14. Epub 2016 Nov 29. Review. No abstract available.

29.

Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review.

Pareek V, Welch M, Ravera E, Zampolin RL, Sequist LV, Halmos B.

J Thorac Oncol. 2016 Nov;11(11):e135-e139. doi: 10.1016/j.jtho.2016.07.010. Epub 2016 Jul 25. Review. No abstract available.

30.

Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.

Yu CC, Qiu W, Juang CS, Mansukhani MM, Halmos B, Su GH.

Cancer Lett. 2017 Jan 1;384:86-93. doi: 10.1016/j.canlet.2016.10.013. Epub 2016 Oct 8. Review.

31.

New twists in the AXL(e) of tumor progression.

Halmos B, Haura EB.

Sci Signal. 2016 Oct 4;9(448):fs14. Review.

PMID:
27703029
32.

Update in Lung Cancer 2015.

Spira A, Halmos B, Powell CA.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):661-71. doi: 10.1164/rccm.201604-0898UP. No abstract available.

33.

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.

Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai JM, Halmos B, Perez-Soler R, Zang X.

Clin Cancer Res. 2017 Feb 1;23(3):825-832. doi: 10.1158/1078-0432.CCR-15-3071. Epub 2016 Aug 23.

34.

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.

Yong KJ, Basseres DS, Welner RS, Zhang WC, Yang H, Yan B, Alberich-Jorda M, Zhang J, de Figueiredo-Pontes LL, Battelli C, Hetherington CJ, Ye M, Zhang H, Maroni G, O'Brien K, Magli MC, Borczuk AC, Varticovski L, Kocher O, Zhang P, Moon YC, Sydorenko N, Cao L, Davis TW, Thakkar BM, Soo RA, Iwama A, Lim B, Halmos B, Neuberg D, Tenen DG, Levantini E.

Sci Transl Med. 2016 Aug 3;8(350):350ra104. doi: 10.1126/scitranslmed.aad6066.

PMID:
27488898
35.

An analysis of the relationship between metastases and cachexia in lung cancer patients.

Shiono M, Huang K, Downey RJ, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk AC, Inoue A, Halmos B, Acharyya S.

Cancer Med. 2016 Sep;5(9):2641-8. doi: 10.1002/cam4.841. Epub 2016 Aug 3.

36.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.

J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22.

37.

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A.

Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. No abstract available.

PMID:
27125205
38.

Has MET met its match?

Borczuk A, Paucar D, Halmos B.

Ann Transl Med. 2016 Mar;4(5):97. doi: 10.21037/atm.2016.01.15. No abstract available.

39.

Recent advances in the management of pulmonary sarcomatoid carcinoma.

Shum E, Stuart M, Borczuk A, Wang F, Cheng H, Halmos B.

Expert Rev Respir Med. 2016 Apr;10(4):407-416. doi: 10.1586/17476348.2016.1157475. Epub 2016 Mar 10.

PMID:
26962707
40.

Sunitinib activates Axl signaling in renal cell cancer.

van der Mijn JC, Broxterman HJ, Knol JC, Piersma SR, De Haas RR, Dekker H, Pham TV, Van Beusechem VW, Halmos B, Mier JW, Jiménez CR, Verheul HM.

Int J Cancer. 2016 Jun 15;138(12):3002-10. doi: 10.1002/ijc.30022. Epub 2016 Mar 1.

41.

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.

Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R, Halmos B.

Oncotarget. 2016 May 17;7(20):28976-88. doi: 10.18632/oncotarget.6721.

42.

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R.

Cancer Discov. 2015 Dec;5(12):1262-70. doi: 10.1158/2159-8290.CD-14-0971. Epub 2015 Sep 14.

43.

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA, Mekhail T, Snell M, Kuebler JP, Sharma N, Dowlati A.

Oncologist. 2015 Nov;20(11):1298-303. doi: 10.1634/theoncologist.2015-0136. Epub 2015 Aug 25.

44.

Update in Lung Cancer 2014.

Spira A, Halmos B, Powell CA.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):283-94. doi: 10.1164/rccm.201504-0756UP. Review.

45.

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, Mansukhani M, Koul S, Halmos B, Borczuk AC.

J Clin Oncol. 2016 Mar 10;34(8):794-802. doi: 10.1200/JCO.2015.62.0674. Epub 2015 Jul 27.

PMID:
26215952
46.

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?

Wang TJ, Saad S, Qureshi YH, Jani A, Nanda T, Yaeh AM, Rozenblat T, Sisti MB, Bruce JN, McKhann GM, Lesser J, Halmos B, Stoopler MB, Lassman AB, Cheng SK, Isaacson SR.

Neuro Oncol. 2015 Jul;17(7):1022-8. doi: 10.1093/neuonc/nov043. Epub 2015 Apr 24.

47.

PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.

Wang X, Li G, Koul S, Ohki R, Maurer M, Borczuk A, Halmos B.

Oncotarget. 2015 Apr 9;9(38):24914-24926. doi: 10.18632/oncotarget.3674. eCollection 2018 May 18.

48.

AXL kinase as a novel target for cancer therapy.

Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B.

Oncotarget. 2014 Oct 30;5(20):9546-63. Review.

49.

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.

Li G, Wang X, Hibshoosh H, Jin C, Halmos B.

PLoS One. 2014 Sep 19;9(9):e106349. doi: 10.1371/journal.pone.0106349. eCollection 2014.

50.

Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples.

Heymann JJ, Bulman WA, Maxfield RA, Powell CA, Halmos B, Sonett J, Beaubier NT, Crapanzano JP, Mansukhani MM, Saqi A.

Cytojournal. 2014 May 22;11:12. doi: 10.4103/1742-6413.132989. eCollection 2014.

Supplemental Content

Loading ...
Support Center